NFE2L2

Across TCGA pan-cancer cohorts, NFE2L2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NFE2L2 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher NFE2L2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NFE2L2 expression acts as an unfavorable survival marker, although some lineages such as CESC and UCEC show a favorable association.

ESCA, COAD, and HNSC are the cancer types where NFE2L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.299	0.549	<.001	24	view →
COAD	DFS	Median	All	0.192	0.696	.005	20	view →
HNSC	DFS	Median	IV	0.405	0.649	.021	15	view →
LGG	DFS	Median	All	0.172	0.845	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	All	0.461	0.728	.012	6	view →
CESC	DFS	Median	III,IV	1.000	0.679	.044	2	view →
UCEC	DFS	Median	II,III,IV	0.834	0.437	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NFE2L2–ESCA (DFS)

Open the ESCA breakdown →